Research programme: SHP2 inhibitors - Astex Pharmaceuticals/Taiho Pharmaceuticals
Latest Information Update: 05 Feb 2021
At a glance
- Originator Astex Pharmaceuticals; Taiho Pharmaceutical
- Class Antineoplastics; Small molecules
- Mechanism of Action Protein tyrosine phosphatase non-receptor type 11 modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Cancer
Most Recent Events
- 13 Jan 2021 Taiho and Astex granted an exclusive license to Merck-Sharp-and-Dohme-Corp.
- 25 Oct 2020 Pharmacodynamics data from preclinical studies in Cancer presented at the 32nd EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics 2020
- 24 Oct 2020 Preclinical trials in Cancer in Japan (PO)